Details of Disease

General Information of Disease (ID: DISQYLV3)

Disease Name	Ewing sarcoma
Synonyms	neuroepithelioma; Ewing's sarcoma/peripheral primitive neuroectodermal tumour; Ewings sarcoma-primitive neuroectodermal tumour; peripheral primitive neuroectodermal tumour; Ewing tumour; localized Ewing's sarcoma/peripheral primitive neuroectodermal tumor; sarcoma, Ewing's; Ewings sarcoma-primitive neuroectodermal tumor; localised peripheral primitive neuroectodermal tumour; localised Ewing's tumour; localized Ewing sarcoma; Ewing tumor; localized Ewing's sarcoma; localised Ewing sarcoma; localised Ewing's sarcoma/peripheral primitive neuroectodermal tumour; neuroepithelioma, peripheral; localised Ewing's sarcoma; localized Ewing's tumor; localized peripheral primitive neuroectodermal tumor; Ewing sarcoma; Ewing's family localised tumour; Ewings sarcoma; Ewing's sarcoma; Ewing's tumor; ES; Ewing's tumour; PNET of Thoracopulmonary region; Ewing's family localized tumor
Disease Class	2B52: Ewing sarcoma
Definition	A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.
Disease Hierarchy	DISYKSRF: Genetic disease DISZDG3U: Sarcoma DISD4VQC: Ewing sarcoma/peripheral primitive neuroectodermal tumor DISQYLV3: Ewing sarcoma
ICD Code	ICD-11 ICD-11: 2B52 ICD-9 ICD-9: 170 Expand ICD-9 170
Disease Identifiers	MONDO ID MONDO_0012817 MESH ID D012512 UMLS CUI C0553580 OMIM ID 612219 MedGen ID 107816 HPO ID HP:0012254 Orphanet ID 319 SNOMED CT ID 76909002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MK-4827	DMLYGH4	Phase 3	Small molecular drug	[1]
FANG vaccine	DM0OV22	Phase 2	Vaccine	[2]
pbi-shRNA EWS-FLI-Type 1	DM0O2N4	Phase 1	Short hairpin RNA	[3]
Seclidemstat	DMCP7SD	Phase 1	Small molecular drug	[4]
TK216	DMTGLOY	Phase 1	NA	[1]
Ganitumab	DM9ERIT	Clinical trial	NA	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 50 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BRD4	TTSRAOU	Limited	Biomarker	[6]
TARDBP	TT9RZ03	Limited	Biomarker	[7]
FOXO1	TTLRVIA	Disputed	Genetic Variation	[8]
FCGRT	TTKLPHO	moderate	Biomarker	[9]
FOLH1	TT9G4N0	moderate	Biomarker	[10]
TIE1	TTT4236	moderate	Altered Expression	[11]
ABHD6	TTSINOV	Strong	Biomarker	[12]
ADAMTS4	TTYG6BU	Strong	Altered Expression	[13]
ADRB3	TTMXGCW	Strong	Biomarker	[14]
AURKB	TT9RTBL	Strong	Biomarker	[15]
CALCB	TTUZ9GV	Strong	Biomarker	[16]
CBL	TT7QT13	Strong	Genetic Variation	[17]
CD248	TTYJWT7	Strong	Biomarker	[18]
CDK12	TTJ21A9	Strong	Biomarker	[19]
CDK4	TT0PG8F	Strong	Biomarker	[20]
CXCR4	TTBID49	Strong	Biomarker	[21]
DCLK3	TTMYK4Z	Strong	Biomarker	[22]
DKK2	TTST5KX	Strong	Biomarker	[23]
DTL	TT8396I	Strong	Altered Expression	[24]
E2F3	TTWIJYH	Strong	Altered Expression	[25]
EED	TTFNJ4R	Strong	Biomarker	[26]
EPHA2	TTRJB2G	Strong	Biomarker	[27]
ERF	TTGXULC	Strong	Altered Expression	[28]
FGF4	TTCEKVZ	Strong	Biomarker	[29]
FOXQ1	TTEJZOL	Strong	Biomarker	[30]
FUS	TTKGYZ9	Strong	Biomarker	[31]
HDGF	TTKGV26	Strong	Biomarker	[32]
IL31RA	TT9HPX0	Strong	Biomarker	[33]
KCNA5	TTW0CMT	Strong	Posttranslational Modification	[34]
KDM1B	TT8VP2T	Strong	Posttranslational Modification	[35]
KDM3A	TTKXS4A	Strong	Biomarker	[36]
KRT17	TTKV0EC	Strong	Biomarker	[37]
LANCL1	TTZW8NS	Strong	Altered Expression	[38]
LIF	TTGZ5WN	Strong	Genetic Variation	[39]
LINGO1	TTZYQ80	Strong	Biomarker	[40]
MAP3K3	TTJZNIG	Strong	Biomarker	[41]
NES	TTHZ752	Strong	Altered Expression	[42]
NPTX2	TTNJ5A6	Strong	Posttranslational Modification	[43]
NR0B1	TTTK36V	Strong	Genetic Variation	[44]
PHGDH	TT8DRCK	Strong	Altered Expression	[45]
PTPN13	TT405FP	Strong	Altered Expression	[46]
RHD	TTLCKI8	Strong	Biomarker	[47]
ROCK2	TTGWKQJ	Strong	Biomarker	[48]
SLC1A5	TTF7WRM	Strong	Altered Expression	[45]
SPN	TTOZAX0	Strong	Altered Expression	[49]
SPRY1	TT0PSN6	Strong	Biomarker	[50]
STEAP1	TT9E64S	Strong	Biomarker	[51]
STRAP	TT165DP	Strong	Biomarker	[52]
TMPRSS2	TT1GM2Z	Strong	Biomarker	[53]
TSPAN7	TTMT6VE	Strong	Altered Expression	[54]
------------------------------------------------------------------------------------


⏷ Show the Full List of 50 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC6	DT582KR	Strong	Biomarker	[55]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP2C8	DES5XRU	Strong	Genetic Variation	[56]
GSTM4	DERQ52Z	Strong	Biomarker	[57]
MGST1	DEAPJSO	Strong	Altered Expression	[58]
------------------------------------------------------------------------------------

This Disease Is Related to 99 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CIZ1	OT3UKHPI	Limited	Biomarker	[59]
PGP	OT6QQ7OR	Limited	Altered Expression	[60]
EGR2	OTAVQ78J	moderate	Genetic Variation	[61]
EMD	OTR8ZANE	moderate	Biomarker	[62]
FNDC5	OT5CSK9X	moderate	Biomarker	[9]
MCF2	OTB9N93T	moderate	Altered Expression	[63]
NECTIN2	OTIE0W6O	moderate	Altered Expression	[64]
OLFM1	OTOYPEWW	moderate	Biomarker	[9]
PAX7	OTDMQRPO	moderate	Altered Expression	[65]
SLFN11	OTJWFPMY	moderate	Altered Expression	[66]
SMARCA5	OT5GR4Z2	moderate	Altered Expression	[67]
TNNT1	OT8PBOAR	moderate	Biomarker	[9]
AKT1S1	OT4JHN4Y	Strong	Biomarker	[68]
ARHGAP1	OT0H2ZBZ	Strong	Altered Expression	[69]
ARMH1	OTTJC0D6	Strong	Altered Expression	[38]
ATG4B	OTQ4RNRM	Strong	Biomarker	[70]
BANF1	OTP7Z38L	Strong	Biomarker	[71]
BCL11B	OT8KKCVJ	Strong	Altered Expression	[72]
BCOR	OTG013AX	Strong	Biomarker	[73]
BORCS5	OTAT6H8Q	Strong	Biomarker	[74]
CACUL1	OT6P1ZVP	Strong	Biomarker	[75]
CAVIN1	OTFO915U	Strong	Genetic Variation	[76]
CCN3	OTOW5YL4	Strong	Altered Expression	[77]
CCNB3	OT5V72D3	Strong	Biomarker	[78]
CCNL1	OTAJSS3D	Strong	Biomarker	[79]
CD79A	OTOJC8DV	Strong	Biomarker	[49]
CEP41	OTKZTBOX	Strong	Genetic Variation	[43]
CHP1	OTHTXN1A	Strong	Genetic Variation	[80]
CNMD	OTHND8EL	Strong	Biomarker	[81]
COL11A2	OT3BQUBH	Strong	Biomarker	[82]
DDIT3	OTI8YKKE	Strong	Biomarker	[83]
DNER	OT2GH2E5	Strong	Altered Expression	[6]
E2F4	OTB3JFH4	Strong	Altered Expression	[25]
EBNA1BP2	OTBRVMZH	Strong	Altered Expression	[38]
ELAVL2	OT6EJ8MQ	Strong	Biomarker	[84]
EMG1	OTFDX7HY	Strong	Biomarker	[33]
ERVFRD-1	OT3064D7	Strong	Biomarker	[85]
ETV1	OT6PMJIK	Strong	Altered Expression	[86]
EYA3	OTHLP1J3	Strong	Biomarker	[87]
FATE1	OTPYXV64	Strong	Biomarker	[88]
FBXW11	OT2A6RLR	Strong	Biomarker	[89]
FEV	OTYEC4IR	Strong	Genetic Variation	[31]
FLII	OT7G9JG6	Strong	Biomarker	[90]
FOXP4	OTHCGIEZ	Strong	Biomarker	[91]
GAB1	OTQKE6V4	Strong	Altered Expression	[92]
GLG1	OT7X0W3N	Strong	Biomarker	[72]
GRB10	OTCKXGRC	Strong	Genetic Variation	[93]
HEATR3	OTB52FZ4	Strong	Biomarker	[94]
HLA-DOA	OTZE5Q7R	Strong	Genetic Variation	[95]
HOXD11	OT9XGA4G	Strong	Biomarker	[96]
IGF2BP3	OTB97VIK	Strong	Biomarker	[97]
IHH	OT1DWGXC	Strong	Altered Expression	[8]
INSM1	OTG8RV8E	Strong	Biomarker	[98]
JTB	OT314JB6	Strong	Altered Expression	[99]
LMO3	OTR7AJHN	Strong	Biomarker	[74]
LRWD1	OTHRVJQC	Strong	Biomarker	[100]
MAML3	OTZFV53Z	Strong	Genetic Variation	[101]
MARCHF8	OTH7PNN2	Strong	Biomarker	[102]
MEIS1	OTH9DKAD	Strong	Altered Expression	[103]
MLXIP	OT30UNI7	Strong	Biomarker	[102]
MRPL41	OTG5URO4	Strong	Genetic Variation	[104]
MYLIP	OTL0PFGV	Strong	Biomarker	[102]
NFATC2	OTK5T6HZ	Strong	Genetic Variation	[105]
NKAP	OT7K7I8Q	Strong	Biomarker	[106]
NKX2-2	OTDCOYNG	Strong	Altered Expression	[107]
NME2	OTCYGLHV	Strong	Altered Expression	[108]
NNAT	OTNRLO7G	Strong	Biomarker	[109]
PAK3	OT80M3BV	Strong	Biomarker	[55]
PAPPA	OTTTG9PG	Strong	Biomarker	[110]
PAX3	OTN5PJZV	Strong	Biomarker	[111]
PHF11	OT5F6LUP	Strong	Biomarker	[43]
PHF19	OTF6RUCR	Strong	Altered Expression	[6]
PPRC1	OT6GB3WR	Strong	Altered Expression	[112]
PRF1	OTFVXD7H	Strong	Biomarker	[113]
PRIMA1	OT9ITT3P	Strong	Biomarker	[114]
PRMT8	OT3MRK62	Strong	Posttranslational Modification	[115]
PSMD7	OT7PZZ4K	Strong	Altered Expression	[38]
PSPH	OTV1PVAX	Strong	Biomarker	[116]
PTPRD	OTZPJ3GX	Strong	Genetic Variation	[93]
RABEPK	OTCZSREH	Strong	Altered Expression	[38]
RAMP1	OT7UT2XB	Strong	Biomarker	[16]
RASSF2	OT2JHDO4	Strong	Posttranslational Modification	[43]
REEP5	OTZU4TJI	Strong	Biomarker	[117]
RHOV	OTW4N3QN	Strong	Genetic Variation	[80]
RITA1	OTUH8IPS	Strong	Biomarker	[118]
RNF2	OTFPLOIN	Strong	Biomarker	[119]
SCG2	OTXWUQQL	Strong	Biomarker	[120]
SH2D1B	OTZG59LW	Strong	Biomarker	[121]
SH2D4B	OTM0KLPH	Strong	Altered Expression	[122]
SNRPN	OTQB1ID1	Strong	Biomarker	[123]
STAG1	OT564IX4	Strong	Altered Expression	[124]
TAF15	OTNE038N	Strong	Biomarker	[7]
TARBP2	OT1QQ8H3	Strong	Altered Expression	[125]
TLE1	OT50MRZ1	Strong	Biomarker	[126]
TP53I3	OTSCM68G	Strong	Genetic Variation	[104]
TRIB1	OTPEO17G	Strong	Biomarker	[30]
TRIP6	OTIPA4ZR	Strong	Altered Expression	[127]
SSX1	OTZ7NRCY	Definitive	Biomarker	[128]
STAG2	OTR6X1Q7	Definitive	Genetic Variation	[129]
------------------------------------------------------------------------------------


⏷ Show the Full List of 99 DOT(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT02736565) Pbi-shRNA EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT03600649) Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas. U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.Cancer Res. 2018 Aug 15;78(16):4760-4773. doi: 10.1158/0008-5472.CAN-18-0484. Epub 2018 Jun 13.
7	An autopsy case of frontotemporal lobar degeneration with the appearance of fused in sarcoma inclusions (basophilic inclusion body disease) clinically presenting corticobasal syndrome.Neuropathology. 2016 Feb;36(1):77-87. doi: 10.1111/neup.12232. Epub 2015 Jul 31.
8	Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas.Growth Horm IGF Res. 2014 Aug;24(4):130-6. doi: 10.1016/j.ghir.2014.04.002. Epub 2014 Apr 16.
9	Artificial neural network inference (ANNI): a study on gene-gene interaction for biomarkers in childhood sarcomas.PLoS One. 2014 Jul 15;9(7):e102483. doi: 10.1371/journal.pone.0102483. eCollection 2014.
10	68Ga-PSMA-HBED-CC PET/CT and 18F-FDG PET/CT in Ewing Sarcoma.Clin Nucl Med. 2020 Jan;45(1):e57-e58. doi: 10.1097/RLU.0000000000002764.
11	Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.Mol Oncol. 2016 May;10(5):677-92. doi: 10.1016/j.molonc.2015.12.009. Epub 2015 Dec 20.
12	High expression of the evolutionarily conserved alpha/beta hydrolase domain containing 6 (ABHD6) in Ewing tumors.Cancer Sci. 2009 Dec;100(12):2383-9. doi: 10.1111/j.1349-7006.2009.01347.x. Epub 2009 Sep 4.
13	Expression of ADAMTS4 in Ewing's sarcoma.Int J Oncol. 2010 Sep;37(3):569-81. doi: 10.3892/ijo_00000706.
14	3-Adrenoreceptor Activity Limits Apigenin Efficacy in Ewing Sarcoma Cells: A Dual Approach to Prevent Cell Survival.Int J Mol Sci. 2019 Apr 30;20(9):2149. doi: 10.3390/ijms20092149.
15	High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.Clin Cancer Res. 2019 Jul 15;25(14):4552-4566. doi: 10.1158/1078-0432.CCR-17-0375. Epub 2019 Apr 12.
16	Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma.Cell Death Dis. 2019 Feb 11;10(2):116. doi: 10.1038/s41419-019-1372-0.
17	Relationship of the human protooncogene CBL2 on 11q23 to the t(4;11), t(11;22), and t(11;14) breakpoints.Cytogenet Cell Genet. 1991;56(2):112-5. doi: 10.1159/000133062.
18	Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.Mol Cancer Ther. 2015 Sep;14(9):2081-9. doi: 10.1158/1535-7163.MCT-15-0312. Epub 2015 Jul 16.
19	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.Cancer Cell. 2018 Feb 12;33(2):202-216.e6. doi: 10.1016/j.ccell.2017.12.009. Epub 2018 Jan 18.
20	A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.Clin Cancer Res. 2019 Feb 15;25(4):1343-1357. doi: 10.1158/1078-0432.CCR-18-0372. Epub 2018 Nov 5.
21	The Role of C-X-C Chemokine Receptor Type 4 (CXCR4) in Cell Adherence and Spheroid Formation of Human Ewing's Sarcoma Cells under Simulated Microgravity.Int J Mol Sci. 2019 Dec 2;20(23):6073. doi: 10.3390/ijms20236073.
22	Preclinical Pharmacokinetics and Dosimetry Studies of (124)I/(131)I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models.J Nucl Med. 2019 Oct;60(10):1414-1420. doi: 10.2967/jnumed.118.225409. Epub 2019 Mar 29.
23	DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma.Cancer Res. 2013 Jan 15;73(2):967-77. doi: 10.1158/0008-5472.CAN-12-1492. Epub 2012 Nov 30.
24	Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications.Med Oncol. 2014 Aug;31(8):109. doi: 10.1007/s12032-014-0109-2. Epub 2014 Jul 10.
25	EWS-FLI1 employs an E2F switch to drive target gene expression.Nucleic Acids Res. 2015 Mar 11;43(5):2780-9. doi: 10.1093/nar/gkv123. Epub 2015 Feb 20.
26	Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.Cell Cycle. 2009 Jul 1;8(13):1991-6. doi: 10.4161/cc.8.13.8929. Epub 2009 Jul 5.
27	EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.Int J Cancer. 2018 Sep 1;143(5):1188-1201. doi: 10.1002/ijc.31405. Epub 2018 Apr 16.
28	Suppression of the Ewing's sarcoma phenotype by FLI1/ERF repressor hybrids.Cancer Gene Ther. 2000 Aug;7(8):1188-95. doi: 10.1038/sj.cgt.7700220.
29	Critical role of the fibroblast growth factor signalling pathway in Ewing's sarcoma octamer-binding transcription factor 4-mediated cell proliferation and tumorigenesis.FEBS J. 2019 Nov;286(22):4443-4472. doi: 10.1111/febs.14946. Epub 2019 Jun 12.
30	EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.Cancer Sci. 2018 Sep;109(9):2907-2918. doi: 10.1111/cas.13710. Epub 2018 Jul 18.
31	Ewing sarcoma with FEV gene rearrangements is a rare subset with predilection for extraskeletal locations and aggressive behavior.Genes Chromosomes Cancer. 2020 May;59(5):286-294. doi: 10.1002/gcc.22828. Epub 2019 Dec 3.
32	Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.J Pathol. 2013 Nov;231(3):323-34. doi: 10.1002/path.4241. Epub 2013 Aug 22.
33	Retracted: Long Noncoding RNA SOX2OT Accelerates the Carcinogenesis of Wilms' Tumor Through ceRNA Through miR-363/FOXP4 Axis.DNA Cell Biol. 2018 Nov 27. doi: 10.1089/dna.2018.4420. Online ahead of print.
34	Promoter Methylation Analysis Reveals That KCNA5 Ion Channel Silencing Supports Ewing Sarcoma Cell Proliferation.Mol Cancer Res. 2016 Jan;14(1):26-34. doi: 10.1158/1541-7786.MCR-15-0343. Epub 2015 Nov 16.
35	Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma.Oncotarget. 2019 Jun 11;10(39):3865-3878. doi: 10.18632/oncotarget.26988. eCollection 2019 Jun 11.
36	KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.Int J Biol Macromol. 2019 Apr 1;126:318-325. doi: 10.1016/j.ijbiomac.2018.12.105. Epub 2018 Dec 20.
37	A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.Mol Cell Biol. 2013 Nov;33(22):4448-60. doi: 10.1128/MCB.00241-13. Epub 2013 Sep 16.
38	Adamantinoma-like Ewing Sarcoma of the Salivary Glands: A Newly Recognized Mimicker of Basaloid Salivary Carcinomas.Am J Surg Pathol. 2019 Feb;43(2):187-194. doi: 10.1097/PAS.0000000000001171.
39	Molecular localization of the t(11;22)(q24;q12) translocation of Ewing sarcoma by chromosomal in situ suppression hybridization.Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):887-91. doi: 10.1073/pnas.88.3.887.
40	Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target.Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3603-8. doi: 10.1073/pnas.1521251113. Epub 2016 Mar 15.
41	Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas.Cancer Res. 2010 Feb 15;70(4):1334-43. doi: 10.1158/0008-5472.CAN-09-2795. Epub 2010 Feb 2.
42	Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.Cancer Biomark. 2016 Jun 7;17(1):107-16. doi: 10.3233/CBM-160623.
43	Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma.Epigenetics. 2013 Nov;8(11):1198-204. doi: 10.4161/epi.26266. Epub 2013 Sep 4.
44	Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group.PLoS One. 2014 Aug 5;9(8):e104378. doi: 10.1371/journal.pone.0104378. eCollection 2014.
45	EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.Mol Carcinog. 2018 Oct;57(10):1342-1357. doi: 10.1002/mc.22849. Epub 2018 Jun 19.
46	Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1.Exp Cell Res. 2013 Jan 1;319(1):1-11. doi: 10.1016/j.yexcr.2012.09.003. Epub 2012 Sep 24.
47	Selective Accumulation of Galactomannan Amphiphilic Nanomaterials in Pediatric Solid Tumor Xenografts Correlates with GLUT1 Gene Expression.ACS Appl Mater Interfaces. 2019 Oct 23;11(42):38483-38496. doi: 10.1021/acsami.9b12682. Epub 2019 Oct 10.
48	Prognostic value and functional role of ROCK2 in pediatric Ewing sarcoma.Oncol Lett. 2018 Feb;15(2):2296-2304. doi: 10.3892/ol.2017.7571. Epub 2017 Dec 8.
49	Differentiating lymphoblastic lymphoma and Ewing's sarcoma: lymphocyte markers and gene rearrangement.Mod Pathol. 2001 Nov;14(11):1175-82. doi: 10.1038/modpathol.3880455.
50	EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.Oncogene. 2017 Feb 9;36(6):766-776. doi: 10.1038/onc.2016.244. Epub 2016 Jul 4.
51	STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors.Mol Cancer Res. 2012 Jan;10(1):52-65. doi: 10.1158/1541-7786.MCR-11-0524. Epub 2011 Nov 11.
52	Oncogenic serine-threonine kinase receptor-associated protein modulates the function of Ewing sarcoma protein through a novel mechanism.Cancer Res. 2006 Nov 15;66(22):10824-32. doi: 10.1158/0008-5472.CAN-06-1599.
53	Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer.Genome Res. 2013 Nov;23(11):1797-809. doi: 10.1101/gr.151340.112. Epub 2013 Aug 12.
54	A tetraspanin-family protein, T-cell acute lymphoblastic leukemia-associated antigen 1, is induced by the Ewing's sarcoma-Wilms' tumor 1 fusion pro... Am J Pathol. 2003 Dec;163(6):2165-72.
55	Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.PLoS Med. 2007 Apr;4(4):e122. doi: 10.1371/journal.pmed.0040122.
56	Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome.Ann Oncol. 2016 Sep;27(9):1788-93. doi: 10.1093/annonc/mdw234. Epub 2016 Jun 10.
57	GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.Oncogene. 2009 Nov 19;28(46):4126-32. doi: 10.1038/onc.2009.262. Epub 2009 Aug 31.
58	Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome.J Clin Oncol. 2009 May 1;27(13):2209-16. doi: 10.1200/JCO.2008.19.2542. Epub 2009 Mar 23.
59	Cancer-associated missplicing of exon 4 influences the subnuclear distribution of the DNA replication factor CIZ1.Hum Mutat. 2007 Oct;28(10):993-1004. doi: 10.1002/humu.20550.
60	Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors.Clin Cancer Res. 2000 Feb;6(2):551-8.
61	CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression.Oncotarget. 2016 Nov 22;7(47):77958-77967. doi: 10.18632/oncotarget.12862.
62	Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo. Oncol Rep. 2005 Sep;14(3):751-8.
63	Expression of the dbl proto-oncogene in Ewing's sarcomas.Oncogene. 1989 Jul;4(7):897-900.
64	DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.Cancer Immunol Immunother. 2015 Apr;64(4):409-18. doi: 10.1007/s00262-014-1648-2. Epub 2014 Dec 31.
65	PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours.Histopathology. 2018 Oct;73(4):645-652. doi: 10.1111/his.13689. Epub 2018 Aug 2.
66	SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.Clin Cancer Res. 2015 Sep 15;21(18):4184-93. doi: 10.1158/1078-0432.CCR-14-2112. Epub 2015 Mar 16.
67	A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor.Mod Pathol. 2011 Mar;24(3):333-42. doi: 10.1038/modpathol.2010.201. Epub 2010 Nov 26.
68	PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma.Cancer Res. 2012 Mar 1;72(5):1260-9. doi: 10.1158/0008-5472.CAN-11-2254. Epub 2012 Jan 12.
69	miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.Int J Cancer. 2017 Nov 15;141(10):2062-2075. doi: 10.1002/ijc.30909. Epub 2017 Aug 8.
70	EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells.Int J Mol Med. 2017 Oct;40(4):1217-1225. doi: 10.3892/ijmm.2017.3112. Epub 2017 Aug 29.
71	EWS-FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex.Nucleic Acids Res. 2019 Oct 10;47(18):9619-9636. doi: 10.1093/nar/gkz699.
72	Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets.Oncotarget. 2017 Aug 4;9(2):1587-1601. doi: 10.18632/oncotarget.20098. eCollection 2018 Jan 5.
73	Fine-Needle Aspiration Features of BCOR-CCNB3 Sarcoma.Am J Clin Pathol. 2020 Feb 8;153(3):315-321. doi: 10.1093/ajcp/aqz159.
74	Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression.Oncogene. 2019 Nov;38(47):7200-7215. doi: 10.1038/s41388-019-0914-3. Epub 2019 Sep 5.
75	WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells.Oncogene. 2013 Mar 14;32(11):1441-51. doi: 10.1038/onc.2012.153. Epub 2012 May 28.
76	DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1.Cancer Lett. 2017 Feb 1;386:196-207. doi: 10.1016/j.canlet.2016.11.020. Epub 2016 Nov 25.
77	Prognostic relevance of CCN3 in Ewing sarcoma.Hum Pathol. 2009 Oct;40(10):1479-86. doi: 10.1016/j.humpath.2009.05.008. Epub 2009 Aug 19.
78	An undifferentiated sarcoma with BCOR-CCNB3 fusion transcript - pathological and clinical retrospective study.Neoplasma. 2018;65(4):630-636. doi: 10.4149/neo_2018_171107N716.
79	Overexpression of miR?99b?p inhibits Ewing's sarcoma cell lines by targeting CCNL1.Mol Med Rep. 2015 Sep;12(3):3359-3364. doi: 10.3892/mmr.2015.3888. Epub 2015 Jun 3.
80	Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24.
81	The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma.Mol Oncol. 2017 Sep;11(9):1288-1301. doi: 10.1002/1878-0261.12057. Epub 2017 Aug 21.
82	The Ewing Family of Tumors Relies on BCL-2 and BCL-X(L) to Escape PARP Inhibitor Toxicity.Clin Cancer Res. 2019 Mar 1;25(5):1664-1675. doi: 10.1158/1078-0432.CCR-18-0277. Epub 2018 Oct 22.
83	Specificity of fusion genes in adipocytic tumors.Anticancer Res. 2010 Feb;30(2):661-4.
84	Identifying prognosis and metastasis-associated genes associated with Ewing sarcoma by weighted gene co-expression network analysis.Oncol Lett. 2019 Oct;18(4):3527-3536. doi: 10.3892/ol.2019.10681. Epub 2019 Jul 29.
85	Investigation of Endogenous Retrovirus Sequences in the Neighborhood of Genes Up-regulated in a Neuroblastoma Model after Treatment with Hypoxia-Mimetic Cobalt Chloride.Front Microbiol. 2018 Feb 21;9:287. doi: 10.3389/fmicb.2018.00287. eCollection 2018.
86	A novel PTPRZ1-ETV1 fusion in gliomas.Brain Pathol. 2020 Mar;30(2):226-234. doi: 10.1111/bpa.12776. Epub 2019 Aug 27.
87	EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.Mol Cancer Res. 2012 Aug;10(8):1098-108. doi: 10.1158/1541-7786.MCR-12-0086. Epub 2012 Jun 20.
88	EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival.Mol Cell Biol. 2019 Jun 27;39(14):e00138-19. doi: 10.1128/MCB.00138-19. Print 2019 Jul 15.
89	Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors.Regul Pept. 2002 Oct 15;108(2-3):47-53. doi: 10.1016/s0167-0115(02)00109-x.
90	Ewing's sarcoma in the spinal canal of T12-L3: A case report and review of the literature.Oncol Lett. 2019 Dec;18(6):6157-6163. doi: 10.3892/ol.2019.10958. Epub 2019 Oct 3.
91	LncRNA SOX2 overlapping transcript acts as a miRNA sponge to promote the proliferation and invasion of Ewing's sarcoma.Am J Transl Res. 2019 Jun 15;11(6):3841-3849. eCollection 2019.
92	Grb2-associated binding protein-1 as a biomarker in bone and soft tissue sarcomas.Pathology. 2019 Oct;51(6):610-614. doi: 10.1016/j.pathol.2019.05.003. Epub 2019 Aug 20.
93	Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors.PLoS One. 2014 Aug 13;9(8):e93676. doi: 10.1371/journal.pone.0093676. eCollection 2014.
94	Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines.Oncotarget. 2018 Oct 12;9(80):35141-35161. doi: 10.18632/oncotarget.26216. eCollection 2018 Oct 12.
95	Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma.Genet Test Mol Biomarkers. 2013 Jun;17(6):458-63. doi: 10.1089/gtmb.2012.0488. Epub 2013 Mar 12.
96	The posterior HOXD locus: Its contribution to phenotype and malignancy of Ewing sarcoma.Oncotarget. 2016 Jul 5;7(27):41767-41780. doi: 10.18632/oncotarget.9702.
97	Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy.Clin Cancer Res. 2018 Aug 1;24(15):3704-3716. doi: 10.1158/1078-0432.CCR-17-2602. Epub 2018 Apr 27.
98	INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma.Mod Pathol. 2018 May;31(5):744-752. doi: 10.1038/modpathol.2017.189. Epub 2018 Jan 12.
99	The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma.Oncotarget. 2017 Feb 14;8(7):10980-10993. doi: 10.18632/oncotarget.14091.
100	High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.Gene. 2017 Jan 5;596:137-146. doi: 10.1016/j.gene.2016.10.021. Epub 2016 Oct 17.
101	BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas.Am J Surg Pathol. 2018 May;42(5):604-615. doi: 10.1097/PAS.0000000000000965.
102	miR-185 suppresses progression of Ewing's sarcoma via inhibiting the PI3K/AKT and Wnt/-catenin pathways.Onco Targets Ther. 2018 Nov 9;11:7967-7977. doi: 10.2147/OTT.S167771. eCollection 2018.
103	Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1.Nucleic Acids Res. 2019 Feb 20;47(3):1255-1267. doi: 10.1093/nar/gky1207.
104	Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y.Mol Cancer Res. 2004 May;2(5):296-304.
105	EWSR1-NFATC2 Translocation-associated Sarcoma Clinicopathologic Findings in a Rare Aggressive Primary Bone or Soft Tissue Tumor.Am J Surg Pathol. 2019 Aug;43(8):1112-1122. doi: 10.1097/PAS.0000000000001260.
106	NKAP functions as an oncogene in Ewing sarcoma cells partly through the AKT signaling pathway.Exp Ther Med. 2019 Oct;18(4):3037-3045. doi: 10.3892/etm.2019.7925. Epub 2019 Aug 20.
107	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility.Nat Commun. 2018 Aug 9;9(1):3184. doi: 10.1038/s41467-018-05537-2.
108	High nm23-H1/NDPK-A expression in Ewing tumors: paradoxical immunohistochemical reactivity and lack of prognostic significance.Int J Cancer. 1995 Apr 21;64(2):104-11. doi: 10.1002/ijc.2910640206.
109	Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing sarcoma.Pediatr Blood Cancer. 2013 Sep;60(9):1437-46. doi: 10.1002/pbc.24526. Epub 2013 Mar 18.
110	Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.J Natl Cancer Inst. 2019 Sep 1;111(9):970-982. doi: 10.1093/jnci/djy209.
111	Molecular array analyses of 51 pediatric tumors shows overlap between malignant intracranial ectomesenchymoma and MPNST but not medulloblastoma or atypical teratoid rhabdoid tumor.Acta Neuropathol. 2007 Jun;113(6):695-703. doi: 10.1007/s00401-007-0210-0. Epub 2007 Mar 13.
112	Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.BMC Cancer. 2018 Feb 7;18(1):158. doi: 10.1186/s12885-018-4066-6.
113	Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma.Clin Cancer Res. 2019 Apr 1;25(7):2228-2240. doi: 10.1158/1078-0432.CCR-18-0936. Epub 2018 Nov 12.
114	Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.Br J Cancer. 2013 Nov 12;109(10):2696-704. doi: 10.1038/bjc.2013.635. Epub 2013 Oct 15.
115	Identification of proteins interacting with protein arginine methyltransferase 8: the Ewing sarcoma (EWS) protein binds independent of its methylation state.Proteins. 2008 Sep;72(4):1125-37. doi: 10.1002/prot.22004.
116	Menin regulates the serine biosynthetic pathway in Ewing sarcoma.J Pathol. 2018 Jul;245(3):324-336. doi: 10.1002/path.5085. Epub 2018 May 28.
117	Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression.J Cancer Res Clin Oncol. 2007 Oct;133(10):749-59. doi: 10.1007/s00432-007-0220-2. Epub 2007 May 25.
118	IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.Mol Cancer Ther. 2012 Jun;11(6):1247-56. doi: 10.1158/1535-7163.MCT-11-0913. Epub 2012 Mar 28.
119	RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-B pathway, independently of the fusion oncoprotein.Oncotarget. 2016 Jul 19;7(29):46283-46300. doi: 10.18632/oncotarget.10092.
120	Neural and mesenchymal differentiations in Ewing's sarcoma cell lines. Morphological, immunophenotypic, molecular biological and cytogenetic evidence.Int J Cancer. 1995 Nov 27;63(5):738-43. doi: 10.1002/ijc.2910630522.
121	NK cell recognition of hematopoietic cells by SLAM-SAP families.Cell Mol Immunol. 2019 May;16(5):452-459. doi: 10.1038/s41423-019-0222-4. Epub 2019 Mar 25.
122	EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene.Oncogene. 1996 Dec 19;13(12):2649-58.
123	The Ewing's sarcoma protein interacts with the Tudor domain of the survival motor neuron protein.Brain Res Mol Brain Res. 2003 Nov 6;119(1):37-49. doi: 10.1016/j.molbrainres.2003.08.011.
124	Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts.Elife. 2017 Jul 10;6:e26980. doi: 10.7554/eLife.26980.
125	A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma.Cancer Cell. 2012 Jun 12;21(6):807-21. doi: 10.1016/j.ccr.2012.04.023.
126	The Utility of NKX2.2 and TLE1 Immunohistochemistry in the Differentiation of Ewing Sarcoma and Synovial Sarcoma.Appl Immunohistochem Mol Morphol. 2019 Mar;27(3):174-179. doi: 10.1097/PAI.0000000000000573.
127	The Zyxin-related protein thyroid receptor interacting protein 6 (TRIP6) is overexpressed in Ewing's sarcoma and promotes migration, invasion and cell growth.Biol Cell. 2013 Nov;105(11):535-47. doi: 10.1111/boc.201300041. Epub 2013 Sep 18.
128	NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.Mod Pathol. 2012 Jun;25(6):854-8. doi: 10.1038/modpathol.2012.31. Epub 2012 Mar 2.
129	Cohesin mutations in myeloid malignancies made simple.Curr Opin Hematol. 2018 Mar;25(2):61-66. doi: 10.1097/MOH.0000000000000405.